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Tissue engineering is an emerging discipline that combines the principle of science and engineering. It oﬀers an unlimited source
of natural tissue substitutes and by using appropriate cells, biomimetic scaﬀolds, and advanced bioreactors, it is possible that tissue
engineering could be implemented in the repair and regeneration of tissue such as bone, cartilage, tendon, and ligament. Whilst
repair and regeneration of ligament tissue has been demonstrated in animal studies, further research is needed to improve the bio-
mechanical properties of the engineered ligament if it is to play an important part in the future of human ligament reconstruction
surgery. We evaluate the current literature on ligament tissue engineering and its role in anterior cruciate ligament reconstruction.
1.Introduction
Ligamentous tissue is composed of ﬁbroblasts and an extra-
cellular matrix. Whilst the ﬁbroblast is the main cell type, the
extracellular matrix is predominantly types I and III collagen
with proteoglycans, water, and small amounts of elastin
present [1, 2]. The ﬁbroblasts secrete the extracellular matrix
and also maintain, repair, and regenerate new tissue growth.
Whilst there are no speciﬁc markers to diﬀerentiate ligament
fromtendon,thetotalamountofcollagen,elastin,andprote-
oglycans varies between the two tissues as well as the types
of collagen. The process of ligament healing is complex and
growth factors play an important role [2]. Most studies con-
centrate on the anterior cruciate ligament (ACL) repair as it
is one of the most common injuries and is therefore a good
model for illustrating ligament repair or regeneration [3–7].
The ACL plays an essential role in the smooth motion and
stability of the knee joint and, due to its poor vascularity, has
limited healing capacity [4, 5]. Traditionally, ACL ruptures
have been treated using autografts, allografts, and synthetic
grafts made from polymers. All of these techniques have a
number of disadvantages [4–8].
The speciality of orthopaedics lends itself to tissue engi-
neering. Musculoskeletal tissues are often injured or lost in
trauma and disease and demonstrate limited healing poten-
tial. Whilst orthopaedic surgery has advanced in the use of
cartilage replacement, it remains to be seen whether there
will be a shift from tissue replacement towards tissue regen-
eration [9]. Tissue engineering oﬀers an unlimited source of
natural tissue substitutes. By using appropriate cells, biomi-
metic scaﬀolds, and advanced bioreactors, it is possible that
tissue engineering could be implemented in the repair and
regeneration of tissue such as bone, cartilage, tendon, and
ligament[10].Theuseofcellssigniﬁcantlyimprovesthecon-
struct quality, and in vivo injections of cells into the injured
ligament can accelerate the repair process by laying down
extracellular matrix, releasing growth factors, and triggering
the necessary immune responses [4, 11]. Novel approaches
are being tried including stem cell therapies, use of growth
factors, mechanical loading, and gene therapy to achieve this
end point [1, 2, 11–14].
2.CellSourceandDifferentApproachesin
LigamentTissueEngineering
Whilst it is imperative to use an appropriate cell type to
achieveafunctionalligamentconstruct,littleisknownabout2 Stem Cells International
the optimal cell source for ligament tissue engineering [4].
Ligament cells from diﬀerent sources vary in their growth,
dexamethasone responsiveness, and cell surface marker ex-
pression. All of these factors are important in enabling the
tissue engineers to carefullyselect the optimal cell source and
hence maximise eﬃcacy [15]. The actual source of the cell,
the variation in the behaviour of cells from diﬀerent species,
thepassagenumber,andtheanimalmodelexperimentsmust
also be considered [5, 16]. The options available are mes-
enchymal stem cells (MSC) or primary ﬁbroblasts derived
fromligaments such as the ACL or medial collateralligament
(MCL) [4, 16–19].
Stem cells are immature biological cells which have the
abilitytoproliferate,diﬀerentiate,andregeneratetissues.The
twomaintypesofstemcellsinmammalsareembryonicstem
cells(ESC),formedamatterofdaysaftereggfertilisation,and
nonembryonic stem cells (non-ESC). Nonembryonic stem
cellsare also referred to as adult stem cells and are usuallyob-
tained from the bone marrow of adults. There are two types
of stem cells available from this source: haemopoietic, which
diﬀerentiate into blood cells, and MSCs. The less mature
sources of MSCs such as the placenta and the umbilical cord
blood are still considered non-ESCs whilst fetal stem cells are
considered an intermediate cell type [20, 21].
Since the discovery of MSCs in 1976, it has become more
apparent that their capacity to repair tissue is due to their
ability to secrete soluble factors which alter the tissue micro-
environment. A number of chemokines and cytokine recep-
tors have been implicated in guiding the MSCs to the zone
of tissue injury to allow tissue repair to begin. Despite this,
there is little evidence with regard to the mechanism of mo-
bilisation of MSCs from the bone marrow. One of their
most important features is their unexplained immunological
properties. Adult MSCs express moderate levels of class I
major histocompatibility complex (MHC) proteins but no
class II proteins. Their nonimmunogenicity indicates that
immunosuppressive therapy is not required if transplanted
into an allogenic host [20].
Bone marrow is the most popular source used to acquire
MCSs due to its relative ease of access. The MSCs of bone
marrow have a greater transdiﬀerentiation capability com-
pared to the MSCs of diﬀerent tissue origin. However, bone
marrow aspiration is invasive, potentially painful, and asso-
ciated with increased risks of morbidity and infection. Other
sources for MSCs have been discovered including amniotic
ﬂuid, umbilical cord blood, adipose tissue, synovium, and
tendon but it is currently unclear which lineages these MSCs
can diﬀerentiate into [20, 22].
3.Mesenchymal StemCells in
LigamentTissueEngineering
The literature would suggest that MSCs are the preferred
method of ligament tissue engineering because they can eas-
ily diﬀerentiate into ligament ﬁbroblasts after two weeks
[1,2,4,5,12,14,16,18,23–26].Inlargeanimalmodelexper-
iments involving pigs, MSCs (passage 2) exhibited ﬁbroblast
phenotype and diﬀerentiation at 24 weeks postoperatively
with silk-based scaﬀolds [5]. Most of the studies use MSCs
at passage 2 [5, 12, 27, 28]. Following passages 2 and 3 at
25–30 days, rabbit MSCs have been shown to have stopped
proliferation, increased in size, and assumed an irregular
morphology. However, this might not be true for hMSCs
[4]. Interestingly, Ge et al. found no diﬀerence in collagen
production between passage 1 and 2 using rabbit MSCs [4].
Furthermore, it has been reported that MSCs lose their po-
tential for osteogenic diﬀerentiation after passage 5-6 due to
senescence or ﬁbroblast contamination [29]. This may have
important implications in ligament tissue engineering where
MSCs are expected to diﬀerentiate into ﬁbroblastic lineage
and therefore achieve pure MSC culture. There are currently
no speciﬁc markers that can reliably distinguish between
MSCs and ﬁbroblasts [29].
There is also the issue regarding the source of MSCs.
Traditionally, MSCs have been harvested from bone marrow
and other sources such as adipose tissue and cord blood.
The potential role for harvesting MSCs from synovial ﬂuid
inligamentregenerationhasalsobeenreported[25,30].The
numberofMSCsisknowntoincreasefollowinganyligament
injury and in degenerative disorders such as osteoarthritis
[30,31].Chengetal.reportedbetteroutcomesfromthestem
cells derived from the ACL itself compared to bone-marrow-
derived MSCs [32].
A bioreactor uses various combinations of chemical, me-
chanical, electrical, or magnetic stimulation to accelerate the
process of diﬀerentiation of MSCs into the ﬁbroblastic lin-
eage and facilitate the development of a de novo tissue con-
struct that is comparable to the desired tissue [33].
There are number of key bioreactor principles that must
be obeyed for the bioreactor to function successfully. The
bioreactor should be designed to operate under strict sterile
conditions in order to prevent contamination of the neotis-
sue with microorganisms. The bioreactor should maintain
accurate control of the physiological environment of the
tissue culture. This ensures control of parameters such as pH
values, oxygen concentrations, temperature and metabolite
concentrations. The bioreactor should provide the culture
with the fundamental nutrients and gases. Finally, the bio-
reactor should be able to accommodate the culture of more
than two cell types at the same time. This is particularly
relevant when engineering complex tissues [33].
Chemical stimulation techniques employ a cocktail of
polypeptides known as growth factors. Growth factors such
as transforming growth factor-β (TGF-β) and epidermal
growth factor (EGF), TGF-β and insulin (maybe in a sequen-
tialapproach),insulin-likegrowthfactor(IGF-I),basicﬁbro-
blast growth factor (bFGF), vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF), or
growth and diﬀerentiation factor (GDF) can expedite the
MSCs to diﬀerentiate into ﬁbroblasts and also improve the
cell proliferation and extracellular matrix deposition [1, 12,
25, 27, 34]. Sustaining suﬃcient quantities of growth factor
within the local tissue has been diﬃcult until the introduc-
tionofgenetransfertechnology[21].Weietal.experimented
bytransfectingbone-marrow-derivedMSCswithadenovirus
vector encoding TGF-β1, VEGF, or TGF-β1/VEGF before
surgical implantation into experimental ACL grafts [24].
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the performance of the MSCs by promoting angiogenesis.
The best mechanical properties were achieved at 24 weeks.
Mechanical conditioning is another method used to in-
ducediﬀerentiationofMSCsintotheﬁbroblastlineage.Trig-
gering the cell surface stretch receptors results in activation
of the intracellular signalling cascades leading to synthesis
of the necessary extracellular matrix proteins [12, 27, 28].
Altman et al. developed a specialised bioreactor for this pur-
pose and found that helically organised collagen ﬁbres form-
ed in the direction of the load [28]. Cocultures are rapidly
becoming popular to promote MSC diﬀerentiation by grow-
ing them together with ﬁbroblasts [12, 35, 36]. The mecha-
nism of action is based both on the cell-to-cell interactions
between the ﬁbroblasts and MSCs and on the cytokines
released within the 3-dimensional environment. The diﬀer-
entiated MSCs are also stimulated to secrete more extracellu-
lar matrix [12]. In one study, fascia was wrapped around the
MSC-seeded ACL tissue construct and, whilst this promoted
extracellular matrix production, it did not enhance the ulti-
mate tensile load and stiﬀness [37].
Experiments using electromagnetic stimulation tech-
niques have been carried out and demonstrate positive ﬁnd-
ings. In one study, a single shot of low-energy laser therapy
was administered to the medial collateral ligament of a rat
resulting in a signiﬁcant increase in the collagen ﬁbril size.
Another study reported an increase in osteoblastic and alka-
line phosphatase activity when electrical stimulation was ap-
plied to rabbit bone marrow [33].
Oe et al. studied ligament regeneration in rats following
intra-articular injection of either fresh bone marrow cells
(BMCs) or cultured MSCs 1 week after partial ACL transec-
tion. At 4 weeks, donor cells were detected within the tran-
sectedACLsinboththeBMCandMSCgroupsandtheACLs
exhibited almost normal histology. Furthermore, there were
signiﬁcantly more mature spindle cells, near normal biome-
chanical properties and higher levels of TGF-β in the ACL
tissue of the BMC group. They concluded that direct intra-
articular bone marrow transplantation is an eﬀective treat-
mentforpartialrupturesoftheACL[3].Similarresultsusing
intra-articular injections have been reported by other re-
searchers [38]. Lim et al. performed ACL reconstructions in
adult rabbits using hamstring tendon autografts which were
coated with MSCs in a ﬁbrin glue carrier. At 8 weeks, good
osteointegration was observed and they performed signiﬁ-
cantlybetteronbiomechanicaltestingthanthecontrols[39].
In summary, MSCs of low passage number are a good
source of cells for use in ligament regeneration. The advan-
tages include: the use of autologous cells, the relative ease of
procurement and growth in the lab and the ability to differ-
entiate into ﬁbroblasts at around 2–4 weeks and secrete the
extracellular matrix.
4. PrimaryFibroblasts in
LigamentTissueEngineering
Fibroblasts are another choice of cell and can be harvested
from diﬀerent sources. Cooper et al. concluded that ACL-
derived ﬁbroblasts were the most suitable cells for the further
study and development of tissue-engineered ligament as
opposed to the cells derived from the MCL, achilles tendon,
or patellar tendon [40]. Another study compared the per-
formance of ﬁbroblasts extracted from both intact and rup-
tured human ACLs. They observed that cells extracted from
the ruptured ACL were more useful in ligament tissue engi-
neering [17]. Fibroblasts from other sources such as the skin
are also being tested for their use in ligament tissue engineer-
ing. However, there is debate as to how well they are able to
function given the change from their normal physiological
environment [4, 41].
5. Comparison between Mesenchymal Stem
Cellsand PrimaryFibroblasts
Ge et al. compared the performance of ﬁbroblasts isolated
from the ACL and MCL to that of bone-marrow-derived
MSCs in rabbits. He found that the proliferation rate and
collagen production were higher with MSCs (passage 1–
37.1mg/mL and passage 2–36.4mg/mL) than with ﬁbrob-
lasts(ACL23.2mg/mLandMCL19.8mg/mL).Thecellssur-
vivedatleast6weeksinthekneejointandintheMSCgroup,
survivorship was due to the protection of the surrounding
fascial covering which led to a mild immune response. All
three groups expressed equal amounts of collagen I, collagen
III, and α-smooth muscle actin [4]. Liu et al. also found
that MSCs grew faster than ﬁbroblasts on silk scaﬀolds. Fur-
thermore,thegeneexpressionfortranscriptsandproduction
was increased in the MSC group compared to the ﬁbroblast
group [16].
6. Response of Cells to Different Biomaterials
in LigamentTissueEngineering
Stem cells are commonly seeded or implanted into a con-
struct that is capable of providing structural support to
three-dimensional tissue growth. These constructs or scaf-
folds facilitate tissue formation by enabling cell migration,
proliferation, and diﬀerentiation [9, 22].
The ideal scaﬀold should have some key properties. The
scaﬀold should be able to bridge any complex three-dimen-
sional anatomical defect, and this can be achieved using sur-
gicalexperienceorthroughsophisticatedcomputermapping
systems. The scaﬀold must provide temporary mechanical
support until the three-dimensional neotissue has regenera-
ted to a mature enough state that the tissue is able to bear
load. A scaﬀold that is biodegradable is often desirable be-
causeabsorptionbythesurroundingtissuepreventstheneed
for surgical removal. However, the rate of absorption must
mirror the rate of neotissue formation. This allows the scaf-
fold to provide a temporary structural mechanical support
until the newly formed tissue takes over the mechanical load.
Porous scaﬀolds enhance tissue regeneration by delivering
biofactors. Pore diameter is important in facilitating cell
migration, proliferation, and growth factor movement. It is
important to get the right balance between tissue regener-
ation and the mechanical properties of the scaﬀold. Whilst4 Stem Cells International
smallerporesareineﬃcient,largerporescancompromisethe
mechanical properties of the scaﬀold [21, 22].
Scaﬀolds can be composed from naturally occurring ma-
terial or from synthetic material. Studies have evaluated the
ability of diﬀerent components within the extracellular ma-
trix to support cell growth. Proteinaceous material such as
collagen and polysaccharidic material such as glycosamino-
glycans(GAGs)havebeenfoundtobesuitablewithregardto
cell compatibility, but immunogenicity remains a potential
problem. Polylactic acid (PLA) is a commonly used synthetic
scaﬀold which easily degrades within the human body by
forminglacticacid.Materialssuchaspolycaprolactone(PCL)
and polyglycolic acid (PGA) degrade in a similar way to PLA
butexhibitdiﬀerentratesofdegradation. Researchcontinues
in the quest to create a scaﬀold that combines the advantages
of both groups of biomaterials [21, 22].
Scaﬀolds that are used in ligament tissue engineering
should mimic the extracellular matrix both by providing ap-
propriate mechanical support and by promoting cellular
adhesion and proliferation [5, 25]. The biomaterials com-
monly used are silk, a variety of polymers (especially poly-
hydroxyesters), and natural substrates such as collagen, gela-
tine, small intestinal submucosal extracellular matrix, and
even decellularised ligaments [5–7, 17, 23, 25, 34, 42, 43].
In a study by Ouyang et al., the adhesion, proliferation, and
morphology of rabbit ACL cells and MSCs were investigated
using diﬀerent biodegradable polymeric ﬁlms. They found
that high molecular weight poly (dl-lactide-co-glycolide)
was most favourable for cell attachment and proliferation
and that MSCs performed better than ACL cells [44]. Knit-
ting,braiding,andelectrospinningareallpopulartechniques
used in the manufacture of biomimetic ﬁbrous scaﬀolds for
ligamenttissueengineering [5,6,19,23,42,43].Thecellsare
proven to spontaneously orientate along the direction of the
ﬁbres leading to abundant extracellular matrix secretion rich
in collagens I and III [5, 42].
Silk is becoming increasingly popular due to its good
biocompatibility, slow degradability, and excellent mechan-
ical properties [5, 6, 34, 45]. Altman et al. popularised silk
scaﬀolds for ligament tissue engineering [45]. They showed
a signiﬁcant increase in the number of cells and matrix pro-
duction after culturing human MSCs for 14 days. Further-
more, mRNA analysis demonstrated a similar gene expres-
sion to native ligament cells. Composite scaﬀolds comprising
silk are extremely biocompatible and both MSCs and pri-
maryﬁbroblastscanattachtothemwithin18hoursandpro-
liferate profusely to secrete extracellular matrix [5, 16, 23, 25,
46]. Sahoo et al. developed a composite electrospun nano-
ﬁbrous PLGA on knitted microﬁbrous silk scaﬀolds. They
were coated with bioactive bFGF, the controlled release of
which was dependent on the degradation of the ﬁbres, facil-
itating MSC attachment, cell proliferation, and ﬁbroblas-
tic diﬀerentiation. This was proven by the upregulation
of ligament speciﬁc extracellular matrix proteins by 14 days
[25, 26]. bFGF is known to stimulate MSC proliferation
anddiﬀerentiationbyactingsynergisticallywiththemechan-
ical stimulation and nanotopographic cues of the scaﬀold
[25].
7. Methods of Characterisingthe
TissueEngineeredLigament
Cellular proliferation, protein synthesis, and extracellular
matrix production are important aspects of ligament tissue
engineering. Characterisation can be performed by histo-
techniques,quantifyingtheextracellularmatrixprotein(per-
haps by immunostaining), scanning electron microscopy, or
quantitativepolymerasechainreactionforgeneexpressionof
relevantligament-relatedproteinssuchascollagentypeIand
relevant transcription factors such as scleraxis, tenomodulin,
and tenascin-C [5, 14, 16, 23, 27, 34, 42, 46–48]. In the case
of MSCs, the protein transcription levels increase by 2 weeks
[16]. Stress-strain tensile testing can be performed for tissue
engineered ligaments to assess their mechanical eﬃciency
[42].
8. Conclusion
Stem cells, growth factors, mechanical loading, biomimetic
scaﬀolds, and gene therapy all play important roles in the
quest to engineer the ideal ligament neotissue. Whilst repair
and regeneration of ligament tissue has been demonstrated
in animal studies, further research is needed to improve the
biomechanical properties of the engineered ligament if it is
to play an important part in the future of human ligament
reconstruction surgery.
Ultimately, randomised controlled trials on human pop-
ulations will be required to demonstrate the clinical applica-
tion of the engineered ligament. Furthermore, a cost-beneﬁt
analysis will be necessary to justify its use over conventional
ACL reconstruction surgery.
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